Literature DB >> 17925418

Prognostic significance of the non-size-based AJCC T2 descriptors: visceral pleura invasion, hilar atelectasis, or obstructive pneumonitis in stage IB non-small cell lung cancer is dependent on tumor size.

Sai-Hong Ignatius Ou1, Jason A Zell, Argyrios Ziogas, Hoda Anton-Culver.   

Abstract

BACKGROUND: The T2 descriptor for staging non-small cell lung cancer (NSCLC) contains several non-size-based criteria. It remains unknown whether the prognostic significance of these non-size-based criteria is dependent on tumor size.
METHODS: A total of 10,545 patients with stage IB NSCLC from the California Cancer Registry between 1989 to 2003 were categorized into the following three nonoverlapping criteria: (1) tumor size (T2S); (2) visceral pleura invasion, hilar atelectasis, or obstructive pneumonitis (T2P); and (3) main bronchus involvement > or = 2 cm from the carina (T2C). Univariate survival analyses were performed using the Kaplan-Meier method. Multivariate survival analyses were performed using Cox proportional hazards ratios.
RESULTS: A total of 51.1% of patients with stage IB NSCLC were staged by T2S, 43.2% by T2P, and 5.7% by T2C; 2,224 stage IB patients (total, 21.1%; 18.9% T2P + 2.2% T2C) had tumors < or = 3 cm in size. The 5-year survival rate and the median survival time of these stage IB patients with tumors < or = 3 cm in size were as follows: T2P, 51.2% and 64 months, respectively; T2C, 49.0% and 58 months, respectively. These values were similar to the 53.2% 5-year survival rate and 67-month median survival time for patients with stage IA NSCLC (p = 0.40). Cox proportional hazards model revealed T2P of > 3 cm was a poor prognostic factor for survival (vs T2S; hazard ratio [HR], 1.16; 95% confidence interval [CI], 1.08 to 1.24). Conversely, T2P < or = 3 cm was a favorable prognostic factor for survival (vs T2S; HR, 0.89; 95% CI, 0.82 to 0.96). T2C was not an independent prognostic factor for survival.
CONCLUSIONS: Prognostic significance of the non-size-based T2 descriptor T2P is dependent on tumor size.

Entities:  

Mesh:

Year:  2007        PMID: 17925418     DOI: 10.1378/chest.07-1306

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  18 in total

1.  Adjuvant therapy for a 3.9-cm adenocarcinoma of the lung.

Authors:  Rebecca Heist; Christopher G Azzoli
Journal:  Oncologist       Date:  2013-11-25

2.  Prognostic effects of preoperative obstructive pneumonitis or atelectasis and comparison with tumor size in non-small cell lung cancer.

Authors:  Zhaofei Pang; Nan Ding; Wei Dong; Yang Ni; Tiehong Zhang; Xiao Qu; Jiajun Du; Qi Liu
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

3.  Visceral pleural invasion does not affect recurrence or overall survival among patients with lung adenocarcinoma ≤ 2 cm: a proposal to reclassify T1 lung adenocarcinoma.

Authors:  Jun-Ichi Nitadori; Christos Colovos; Kyuichi Kadota; Camelia S Sima; Inderpal S Sarkaria; Nabil P Rizk; Valerie W Rusch; William D Travis; Prasad S Adusumilli
Journal:  Chest       Date:  2013-11       Impact factor: 9.410

4.  Association between clinicopathological factors and postoperative radiotherapy in patients with completely resected pathological N2 non-small cell lung cancer.

Authors:  Yujin Xu; Jianqiang Li; Jin Wang; Xiao Hu; Honglian Ma; Pu Li; Xiao Zheng; Ming Chen
Journal:  Oncol Lett       Date:  2017-12-13       Impact factor: 2.967

5.  Peripheral lung adenocarcinomas harboring epithelial growth factor receptor mutations with microRNA-135b overexpression are more likely to invade visceral pleura.

Authors:  Hanbo Le; Xiaoling Wang; Yao Zha; Jie Wang; Wangyu Zhu; Zhinan Ye; Xiaoguang Liu; Haijie Ma; Yongkui Zhang
Journal:  Oncol Lett       Date:  2017-10-16       Impact factor: 2.967

6.  Correlation between tumor measurement on Computed Tomography and resected specimen size in lung adenocarcinomas.

Authors:  Katharine Lampen-Sachar; Binsheng Zhao; Junting Zheng; Chaya S Moskowitz; Lawrence H Schwartz; Maureen F Zakowski; Naiyer A Rizvi; Mark G Kris; Michelle S Ginsberg
Journal:  Lung Cancer       Date:  2011-09-03       Impact factor: 5.705

7.  Relapse in resected lung cancer revisited: does intensified follow up really matter? A prospective study.

Authors:  Dragan Subotic; Dragan Mandaric; Gordana Radosavljevic; Jelena Stojsic; Milan Gajic; Maja Ercegovac
Journal:  World J Surg Oncol       Date:  2009-11-12       Impact factor: 2.754

8.  Re-evaluation of the prognostic value of visceral pleura invasion in Stage IB non-small cell lung cancer using the prospective multicenter ACOSOG Z0030 trial data set.

Authors:  Juan J Fibla; Stephen D Cassivi; Alessandro Brunelli; Paul A Decker; Mark S Allen; Gail E Darling; Rodney J Landreneau; Joe B Putnam
Journal:  Lung Cancer       Date:  2012-10-03       Impact factor: 5.705

9.  Modification of Pathologic T Classification for Non-small Cell Lung Cancer With Visceral Pleural Invasion: Data From 1,055 Cases of Cancers ≤ 3 cm.

Authors:  Run-Bin Liang; Peng Li; Bob T Li; Jie-Tian Jin; Valerie W Rusch; David R Jones; Yi-Long Wu; Qing Liu; Jie Yang; Mu-Zi Yang; Shuo Li; Hao Long; Jian-Hua Fu; Lan-Jun Zhang; Peng Lin; Tie-Hua Rong; Xue Hou; Su-Xia Lin; Hao-Xian Yang
Journal:  Chest       Date:  2021-03-18       Impact factor: 9.410

10.  Prognostic factors of tumor recurrence in completely resected non-small cell lung cancer.

Authors:  Apichat Tantraworasin; Somcharoen Saeteng; Nirush Lertprasertsuke; Nuttapon Arreyakajohn; Choosak Kasemsarn; Jayanton Patumanond
Journal:  Cancer Manag Res       Date:  2013-06-06       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.